Margaret White
Family · Houston, TXNPI 1346651593
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Gilead at 51.2% of the total. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 352 payments — averaging $242.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$44K
- Viiv Healthcare Company$15K
- Theratechnologies Inc.$14K
- Napo Pharmaceuticals Inc$7K
- Merck$5K
- Johnson & Johnson$379
- plus $642 from 10 others
Across 6 payments — averaging $171.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$1K
What the payments were for
- Consulting fees$13,73016%
- Speaking & faculty fees$50,62259%
- Travel & lodging$13,47516%
- Food & beverage$7,5579%
- Education$850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 139 | $43,742 |
| Viiv Healthcare Company | 63 | $15,206 |
| Theratechnologies Inc. | 39 | $13,737 |
| Napo Pharmaceuticals Inc | 24 | $6,967 |
| Merck | 34 | $4,797 |
| Johnson & Johnson(2 entities) | 26 | $379 |
| AbbVie | 3 | $142 |
| Janssen Products, LP | 1 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $79 |
| Eisai Inc. | 4 | $79 |
| Amgen | 5 | $73 |
| Endo Pharmaceuticals Inc. | 4 | $63 |
| Antares Pharma, Inc. | 2 | $38 |
| Novo Nordisk | 2 | $34 |
| EMD Serono, Inc. | 1 | $30 |
| Amarin Pharma, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$85,470 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 123 | $501,532 |
| TrogarzoIbalizumab-Uiyk | 28 | $333,300 |
| SunlencaLenacapavir Sodium | 13 | $204,001 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 36 | $166,842 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 41 | $162,511 |
| RukobiaFostemsavir Tromethamine | 16 | $143,561 |
| CabenuvaCabotegravir/Rilpivirine | 24 | $142,720 |
| PrezcobixDarunavir/Cobicistat | 48 | $119,971 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 26 | $97,813 |
| DovatoDolutegravir Sodium/Lamivudine | 28 | $90,080 |
| Egrifta SvTesamorelin Acetate | 13 | $89,108 |
| TivicayDolutegravir Sodium | 36 | $87,596 |
| DescovyEmtricitabine/Tenofov Alafenam | 32 | $68,250 |
| PifeltroDoravirine | 36 | $60,734 |
| DelstrigoDoravirine/Lamivu/Tenofov Diso | 11 | $29,004 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Sunlenca, Descovy | $43,742 | $773,784168 claims |
| Viiv Healthcare CompanyTriumeq, Rukobia, Cabenuva, Dovato, Tivicay | $15,206 | $626,468145 claims |
| Theratechnologies Inc.Trogarzo, Egrifta Sv | $13,737 | $422,40841 claims |
| Janssen Products, LPSymtuza | $85 | $166,84236 claims |
| Johnson & JohnsonPrezcobix | $379 | $119,97148 claims |
| MerckPifeltro, Delstrigo, Isentress Hd | $4,797 | $113,13659 claims |
| Novo NordiskOzempic | $34 | $20,72623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Houston
- Robin BeachHouston$428K
- Sarah AguilarHouston$199K
- Cheryl HaseebHouston$42K
- Kendrick ClackHouston$28K
- David WeirDallas$959K
- April LopezMcAllen$417K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.